ImmuCell (ICCC) CEO increases stake with 8,000-share open-market buy

Rhea-AI Filing Summary

ImmuCell Corp director and CEO Paul Francis Olivier te Boekhorst reported buying additional company stock. On June 18, 2026, he made an open-market purchase of 8,000 shares of ImmuCell common stock at $9.495 per share, bringing his direct holdings to 17,785 shares.

Insider Trade Summary

Net Buyer: 8,000 shares ($75,960)

Net Buy 1 txn

Insider te Boekhorst Paul Francis Olivier

Role President and CEO

Bought 8,000 shs ($76K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $.01 per share	8,000	$9.495	$76K

Holdings After Transaction: Common Stock, par value $.01 per share — 17,785 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 8,000 shares Purchase price: $9.495 per share Shares held after transaction: 17,785 shares +1 more

4 metrics

Shares purchased 8,000 shares Open-market buy on June 18, 2026

Purchase price $9.495 per share Price paid for ImmuCell common stock

Shares held after transaction 17,785 shares Direct ownership following the purchase

Transaction type Open-market purchase (Code P) Non-derivative common stock transaction

Key Terms

open-market purchase, Common Stock, par value $.01 per share, Form 4

3 terms

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock, par value $.01 per share financial

"security_title: "Common Stock, par value $.01 per share""

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

te Boekhorst Paul Francis Olivier

(Last) (First) (Middle)

C/O IMMUCELL CORPORATION

56 EVERGREEN DRIVE

(Street)

PORTLAND MAINE 04103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUCELL CORP /DE/ [ ICCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $.01 per share	06/18/2026	06/18/2026	P		8,000	A	$9.495	17,785	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Timothy C. Fiori Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ImmuCell (ICCC) report in this Form 4?

ImmuCell reported that its President and CEO, Paul Francis Olivier te Boekhorst, executed an open-market purchase of 8,000 shares of common stock at a price of $9.495 per share, increasing his direct ownership stake in the company.

How many ImmuCell (ICCC) shares did the CEO hold after the reported trade?

After the reported open-market purchase, Paul Francis Olivier te Boekhorst directly held 17,785 shares of ImmuCell common stock. This figure reflects his position following the acquisition of 8,000 additional shares disclosed in the Form 4 filing.

Was the ImmuCell (ICCC) CEO’s transaction a purchase or sale?

The transaction was a purchase. The Form 4 specifies a transaction code “P” and describes it as an open-market purchase, indicating that the CEO bought 8,000 ImmuCell common shares rather than selling or disposing of stock.

At what price did the ImmuCell (ICCC) CEO buy his new shares?

The CEO bought the new ImmuCell shares at a transaction price of $9.495 per share. This per-share price applies to the entire 8,000-share open-market purchase disclosed in the Form 4 insider trading report.

Does the ImmuCell (ICCC) Form 4 show any stock option exercises?

No stock option exercises are shown in this Form 4. The filing only reports a non-derivative transaction in common stock, specifically an open-market purchase, and the derivativeSummary section contains no remaining derivative positions.